A hepatitis C drug from Santaris targeting a microRNA is now in the early stages of clinical testing, reports Technology Review. The drug, a synthetic nucleic acid, binds miR-122, which the hepatitis C virus needs to reproduce.
A hepatitis C drug from Santaris targeting a microRNA is now in the early stages of clinical testing, reports Technology Review. The drug, a synthetic nucleic acid, binds miR-122, which the hepatitis C virus needs to reproduce.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.